Access and Utilization of New Antidepressant and Antipsychotic Medications 2000 Office of Health Policy 
Affording Prescription Drugs Not Just a Problem for the Elderly 2002 Peter J. Cunningham Center for Studying Health System Change
Audit of the Pharmacare Program Manitoba Health 2006 Manitoba Office of the Auditor General 
Canadian Adverse Drug Reaction Monitoring Program (CADRMP) Adverse Reaction Database - this Health Canada database contains information on suspected adverse reactions to Canadian marketed health products, including pharmaceuticals, biologics (including blood products and therapeutic and diagnostic vaccines), natural health products, and radiopharmaceuticals 
Canadian Adverse Drug Reaction Newsletter 
Canadian Coordinating Office for Health Technology Assessment
Canadian Pharmacare: Performance, Incentives and Insurance 2005 John R. Graham & Tanya Tabler Fraser Institute
Clinical Governance in Community Pharmacy: Guidelines on Good Practice for the NHS 2001 Department of Health 
Common Drug Review 2002 Annual Conference of Federal-Provincial-Territorial Ministers of Health
Competition and Regulation Issues in the Pharmaceutical Industry OECD
Costs of a Medicare Prescription Drug Benefit: a Comparison of Alternatives 2002 RAND 
DEANS: Drug Evaluation Alliance of Nova Scotia: Annual Summary 2006 Nova Scotia Department of Health 
Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report 2006 Committee on Clinical Trial Registries National Academies Press
Developing Standards for Electronic Prescribing Systems RAND
Direct to Consumer Advertising of Prescription Drugs in New Zealand: For Health or for Profit: Report to the Minister of Health Supporting the Case for a Ban on DTCA 2003 Les Toop, Dee Richards, Tony Dowell, Murray Tilyard, Tony Fraser, Bruce Arroll University of Otago 
Drug Expenditure in Canada 1985 to 2005 2006 Canadian Institute for Health Information
DTCA: Volume 1 Assessment of the Health System Impacts of Direct to Consumer Advertising of Prescription Medications 2001 B. Mintzes, M.L. Barer, A. Kazanjian, K. Bassett, R.G. Evans, S. Morgan HPRU 
DTCA: Volume 2: Literature Review: Direct to Consumer Advertising of Prescription Drugs: What Do We Know Thus Far About Its Effects on Health and Health Care Services? 2001 Barbara Mintzes HPRU
DTCA: Volume 3: Patient Information on Medicines: Comparative/Doctor Survey in Vancouver and Sacramento 2001 Barbara Mintzes, Morris L. Barer, Ken Bassett, Arminee Kazanjian, Robert G. Evans HPRU
DTCA: Volume 4: Pills, Persuasion and Public Health Policies: Report of an Expert Survey on Direct-to-Consumer Advertising of Prescription Drugs in Canada, the United States and New Zealand 2001 Barbara Mintzes, Arminee Kazanjian, Ken Bassett, Joel Lexchin HPRU
DTCA: Volume 5: Predicting the Welfare and Cost Consequences of Direct to Consumer Prescription Drug Advertising 2001 Steve Morgan HPRU
E-Prescribing Peter Kilbridge California HealthCare Foundation
Electronic Prescribing Systems: Making It Safer To Take Your Medicine? 2005 RAND
Electronic Prescribing: Toward Maximum Value and Rapid Adoption: Recommendations for Optimal Design and Implementation to Improve Care, Increase Efficiency and Reduce Costs in Ambulatory Care 2004 e-Health Initiative
High-Cost Users of Pharmaceuticals: Who Are They? 2005 Anita Kozyrskyj, Lisa Lix, Mathew Dahl, Ruth-Ann Soodeen Manitoba Centre for Health Policy
Hospital Funding for New Drug Technologies 2002 M. Mamdani, M. Paterson, A. Laupacis, K. Handa, R. Jacka Institute for Clinical Evaluative Sciences 
Hospital Pharmacy in Canada: Medication Incidents: Annual Reports 2001-2002 Eli Lilly Canada
Improving Drug Prescribing Practices in the Outpatient Setting: a Market Analysis 2002 Melissa Buckley California HealthCare Foundation
International Experience with Pharmaceutical Policy: Common Challenges and Lessons for Canada: CHEPA Working Paper 01-08 2001 Donald Willison, Mary Wiktorowicz, Paul Grootendorst , Bernie O'Brien, Mitchell Levine, Raisa Deber, Jeremiah Hurley Centre for Health Economics and Policy Analysis
Journal of Pharmacy and Pharmaceutical Sciences a publication of the Canadian Society for Pharmaceutical Sciences 
Making Birth Control More Accessible to Women: a Cost-Benefit Analysis of Over-the-Counter Oral Contraceptives 2001 Holly Mead IWPR
Medicines Management 2002 Audit Commission 
Methadone Maintenance Guidelines 2001 College of Physicians and Surgeons of Ontario, CAMH, Ontario College of Pharmacists 
New Brunswick Auditor General's Report 2005 Volume 2 Chapter 5: Department of Health and Wellness Prescription Drug Program 2005 New Brunswick Department of Health and Wellness 
Nonmedical Use of Prescription-Type Drugs Among Youths and Young Adults 2003 SAMHSA
Patented Medicine Prices Review Board: Annual Report 2004 Patented Medicine Prices Review Board
Pharmacare in Canada: Issues and Options Ake Blomquist, Jing Xu Health Canada
Pharmaceutical Issues: Health Transition Fund Synthesis Series 2002 Health Canada
Pharmaceutical Research and Policy: Research Spotlight 2006 Canadian Institutes of Health Research
Pharmaceuticals: Focusing on Appropriate Utilization 2003 Colleen Metge, Anita Kozyrskyj, Matt Dahl, Marina Yogendran, Noralou Roos Manitoba Centre for Health Policy
Pharmaceuticals: Therapeutic Interchange and Pricing Policies 2003 Steve Morgan, Anita Kozyrskyj, Colleen Metge, Noralou Roos, Matt Dahl Manitoba Centre for Health Policy
Pharmacological and Surgical Treatment of Obesity: Summary: Evidence Report/Technology Assessment: Number 103 2004 P.G. Shekelle, S.C. Morton, M. Maglione, et al. Agency for Healthcare Research and Quality
Pharmacotherapy in Children: From Art to Science 2002 RAND Europe
Prescription Drug Coverage, Spending, Utilization and Prices: Report to the President 2000 Department of health and Human Services
Prescription Drug Trends: a Chartbook Update 2001 David H. Kreling, David A. Mott, Jospeh B. Wiederholt, Janet Lundy, Larry Levitt
Prescription Drugs: Abuse and Addiction 2001 National Institute on Drug Abuse
Price and Productivity Measurement in a Pharmaceutical Sector Sub-Market: The Real Cost of Treating Hypertension 2001 S. Morgan HPRU
Primary Care Prescribing 2003 Audit Commission
Production and Use of Evidence of Drug Effectiveness: Systematic Review: Evaluation and a Guidebook for Decision Makers 2004 Health Canada
Rapid and Systematic Review of the Clinical and Cost Effectiveness of Bupropion SR and Nicotine Replacement Therapy (NRT) for Smoking Cessation 2002 N. Woolacott, l. Jones, C. Forbes, L. Mather, A. Sowden, F. Song, J. Raftery, P. Aveyard, C. Hyde, P. Barton NICE
Securing the Benefits of Medical Innovation for Seniors: Role of Prescription Drugs and Drug Coverage 2002 Department of Health and Human Services
Systematic Review of the Clinical Effectiveness and Cost-effectiveness of Sibutramine in the Management of Obesity 2000 Susan O'Meara, Rob Riemsma, Liz Shirran, Lisa mather, Gerben ter Riet NICE
Understanding the Effects of Direct-to-Consumer Prescription Drug Advertising 2001
What Effects Do Provincial Drug Plan Coverage Policies for New Drugs Have on Patterns of Use and Cost? 2003 M. Paterson, K. Bassett, M. Mamdani, J. Wright, G. Naglie, A. Laupacis, G. Anderson Institute for Clinical Evaluative Sciences
Whose Evidence, What Kind of Practice: Profits, Research and Medical Practice Joel Lexchin, 2007 CADTH Symposium
Yukon Drug Programs Formulary 2001 